NCR3抗体

+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 30 μg, Lane: Mouse kidney tissue, Primary antibody: P07083(ANXA6 Antibody) at dilution 1/350, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P07083(ANXA6 Antibody) at dilution 1/17. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P07083(ANXA6 Antibody) at dilution 1/17. (Original magnification: ×200)    

  
  

NCR3 (Natural Cytotoxicity Triggering Receptor 3), also known as NKp30. is a key activating receptor expressed on natural killer (NK) cells and a subset of T cells. It belongs to the immunoglobulin superfamily and plays a critical role in innate immune responses by recognizing stress-induced ligands, such as B7-H6. which are often overexpressed on infected or malignant cells. Engagement of NCR3 with its ligands triggers cytotoxic activity and cytokine production, enabling NK cells to eliminate target cells. Dysregulation of NCR3 signaling has been implicated in immune evasion by tumors and certain pathogens, highlighting its therapeutic relevance.

NCR3-specific antibodies are essential tools for studying receptor-ligand interactions, cellular localization, and functional modulation. In research, these antibodies are used in flow cytometry, immunohistochemistry, and functional assays to dissect NCR3's role in immune surveillance. Therapeutically, anti-NCR3 antibodies are being explored to enhance NK cell-mediated cytotoxicity against cancers or to block inhibitory pathways in chronic infections. For example, agonist antibodies may boost antitumor responses, while antagonist antibodies could mitigate immune exhaustion.

Clinical interest in NCR3 has grown due to its dual role in promoting tumor clearance and its potential contribution to immunosuppressive microenvironments. Studies link altered NCR3 expression or polymorphisms to outcomes in melanoma, leukemia, and viral infections. Challenges remain in understanding ligand diversity, receptor trafficking, and context-dependent signaling. Nonetheless, NCR3 antibodies continue to bridge mechanistic insights and translational applications in immunotherapy.